Source
6 developments in the corpus
Latest
Everything in the corpus, newest first.
OCT 1, 2026 · JOURNAL ARTICLE
Anticancer Research
Background/Aim: The optimal management of close resection margins after breast-conserving surgery (BCS) remains controversial, particularly in hormone receptor-negative (HR−) breas
OCT 1, 2026 · JOURNAL ARTICLE
Anticancer Research
Background/Aim: Neoadjuvant chemotherapy with gemcitabine plus S-1 (NAC–GS) is used for resectable pancreatic cancer, but adverse events prevent some patients from completing plann
OCT 1, 2026 · JOURNAL ARTICLE
Anticancer Research
Background/Aim: Carcinoembryonic antigen (CEA) contributes to colorectal cancer surveillance and has been implicated in colorectal liver metastasis through interaction with the hep
OCT 1, 2026 · JOURNAL ARTICLE
Anticancer Research
Background/Aim: Atezolizumab, bevacizumab, carboplatin, and paclitaxel (ABCP) therapy has demonstrated efficacy in epidermal growth factor receptor (EGFR)-mutated non-small cell lu
OCT 1, 2026 · JOURNAL ARTICLE
Anticancer Research
Background/Aim: Ramucirumab (RAM) plus taxane is the standard second-line treatment for unresectable advanced gastric cancer (AGC). However, the clinical outcomes of this regimen a
OCT 1, 2026 · JOURNAL ARTICLE
Anticancer Research
Background/Aim: Patients with stage IV colorectal cancer and multiple distant metastases are generally treated with systemic chemotherapy. However, treatment options may be limited